GVS (GVS) Q3 2025 earnings summary

Executive summary

• Healthcare and Life Sciences revenues grew 4.8% year-over-year excluding FX and US dialysis, while Safety division revenues increased 8.5% year-over-year, both showing strong momentum; consolidated revenues for the nine months ended 30 September 2025 were €315.6 million, up 0.2% at constant exchange rates.

• Adjusted EBITDA margin improved to 24.9%, up 67 basis points year-over-year, with adjusted EBITDA reaching €78.7 million, a 0.8% increase; adjusted net income rose 7.2% to €36.3 million, with margin improving to 11.5%.

• Net financial position stood at €271.8 million as of September 2025, with a leverage ratio of 2.5x post-M&A and buyback.

• Net income attributable to the group was €9.0 million, down from €19.5 million year-over-year, impacted by higher exchange losses and non-recurring costs.

• The acquisition of Haemonetics' whole blood assets was completed in January 2025, strengthening the Transfusion Medicine segment.

Financial highlights

• Revenue for 9M 2025 was €315.6 million, down 1.9% year-over-year, but up 0.2% at constant exchange rates; Safety (+8.5%) and Healthcare (+0.5%) divisions supported growth.

• Adjusted EBITDA was €78.7 million (up 0.8% year-over-year), with margin improving to 24.9%.

• Adjusted net income margin increased to 11.5% from 10.5% year-over-year.

• Net financial debt increased to €271.8 million, mainly due to M&A and extraordinary investments.

• Ordinary cash generation in nine months was €13 million, despite a €20 million negative working capital trend, expected to recover in Q4.

Outlook and guidance

• FY 2025 guidance projects low single-digit sales growth at constant exchange rates, with adjusted EBITDA margin expected to improve by 100-150 basis points versus FY 2024.

• Leverage ratio projected around 2.2x at year-end 2025, including share buybacks.

• 2026 outlook anticipates new product launches in MedTech and Safety, ramp-up in Transfusion Medicine, and growth in Life Sciences and Mobility, especially in electric vehicles and hydrogen membrane products.